Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis

References

• Andelman S. Y. Etodolac, aspirin, and placebo in patients with degenerative joint disease: twelve-week study. Clin. Ther 1983; 5: 651–6611. Andelman S. Y. Etodolac, aspirin, and placebo in patients with degenerative joint disease: twelve-week study. Clin. Ther 1983; 5: 651–661
   PubMed Web of Science ®Google Scholar
• Arnold J. D., Mullane J. F., Hayden D. M., March L., Hart K., Perdomo C. A. Etodolac, aspirin, and gastrointestinal microbleeding. Clin. Pharmacol. Ther 1984; 35: 716–7212. Arnold J. D., Mullane J. F., Hayden D. M., March L., Hart K., Perdomo C. A. Etodolac, aspirin, and gastrointestinal microbleeding. Clin. Pharmacol. Ther 1984; 35: 716–721
   PubMed Web of Science ®Google Scholar
• Arnold J. D., Salom I. L., Berger A. E., Meinders J. D., Jacob G., Hayden D., Mullane J. E. Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Cur Ther. Res. 1985; 37: 730–7383. Arnold J. D., Salom I. L., Berger A. E., Meinders J. D., Jacob G., Hayden D., Mullane J. E. Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Cur Ther. Res. 1985; 37: 730–738
   Web of Science ®Google Scholar
• Benhamou C. L. Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. Rheumatol. Int. 1990; 10: 29–34, Suppl.4. Benhamou C. L. Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. Rheumatol. Int. 1990; 10: 29–34, Suppl.
   PubMed Web of Science ®Google Scholar
• Briancon D. International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. Clin. Rheumatol. 1989; 8(Suppl. 1)63–725. Briancon D. International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. Clin. Rheumatol. 1989; 8(Suppl. 1)63–72
   PubMedGoogle Scholar
• Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Piroxicam: review of its pharmacological properties and therapeutic efficacy. Drugs 1981; 22: 165–1876. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Piroxicam: review of its pharmacological properties and therapeutic efficacy. Drugs 1981; 22: 165–187
   PubMed Web of Science ®Google Scholar
• Ciompi M. L., Puccetti L., Bazzichi L., Remorini E., Marotta G. Etodolac versus diclofenac: double-blind crossover study in rheumatoid arthritis. Int. J. Clin. Pharm. Res. 1989; 9: 211–2227. Ciompi M. L., Puccetti L., Bazzichi L., Remorini E., Marotta G. Etodolac versus diclofenac: double-blind crossover study in rheumatoid arthritis. Int. J. Clin. Pharm. Res. 1989; 9: 211–222
   Google Scholar
• del Toro R. A. Concepcion R. Twelve-week study of etodolac, aspirin and placebo in patients with rheumatoid arthritis. Clin. Ther 1983; 5: 436–4448. del Toro R. A. Concepcion R. Twelve-week study of etodolac, aspirin and placebo in patients with rheumatoid arthritis. Clin. Ther 1983; 5: 436–444
   PubMed Web of Science ®Google Scholar
• Demerson C. A., Humber L. G., Philip A. H., Martel R. R. Etodolic acid and related compounds. Chemistry and anti-inflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano [3,4–b indole-l-acetic acids. J. Med. Chem. 1976; 19: 391–3959. Demerson C. A., Humber L. G., Philip A. H., Martel R. R. Etodolic acid and related compounds. Chemistry and anti-inflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano [3,4–b indole-l-acetic acids. J. Med. Chem. 1976; 19: 391–395
   PubMed Web of Science ®Google Scholar
• DeQueiros M. F. V. Double-blind comparison of etodolac and naproxen in patients with rheumatoid arthritis. Clin. Ther 1991; 13: 38–4610. DeQueiros M. F. V. Double-blind comparison of etodolac and naproxen in patients with rheumatoid arthritis. Clin. Ther 1991; 13: 38–46
   PubMed Web of Science ®Google Scholar
• Edwards W. Etodolac, aspirin, and placebo in patients with rheumatoid arthritis. A 12-week study. Clin. Ther. 1983; 5: 495–50311. Edwards W. Etodolac, aspirin, and placebo in patients with rheumatoid arthritis. A 12-week study. Clin. Ther. 1983; 5: 495–503
   PubMed Web of Science ®Google Scholar
• Friedrich E. A. A comparison of etodolac (Ultradol) with aspirin and placebo in patients with episiotomy pain. Curr: Ther: Res. 1983; 33: 100–10712. Friedrich E. A. A comparison of etodolac (Ultradol) with aspirin and placebo in patients with episiotomy pain. Curr: Ther: Res. 1983; 33: 100–107
   Web of Science ®Google Scholar
• Gaston G. W., Mallow R. D., Frank J. E. Comparison of etodolac, aspirin, and placebo for pain after oral surgery. Pharmacotherapy 1986; 6: 199–20513. Gaston G. W., Mallow R. D., Frank J. E. Comparison of etodolac, aspirin, and placebo for pain after oral surgery. Pharmacotherapy 1986; 6: 199–205
   PubMed Web of Science ®Google Scholar
• Gordon G. V., Polsky B. G. Three-month trial of etodolac (Ultradol) compared with aspirin and placebo in patients with rheumatoid arthritis. Curr: Ther: Res. 1983; 33: 89–9914. Gordon G. V., Polsky B. G. Three-month trial of etodolac (Ultradol) compared with aspirin and placebo in patients with rheumatoid arthritis. Curr: Ther: Res. 1983; 33: 89–99
   Web of Science ®Google Scholar
• Hutton C. E. The effectiveness of 100 and 200 mg etodolac (Ultradol), aspirin, and placebo in patients with pain following oral surgery. Oral Surg. 1983; 56: 575–58015. Hutton C. E. The effectiveness of 100 and 200 mg etodolac (Ultradol), aspirin, and placebo in patients with pain following oral surgery. Oral Surg. 1983; 56: 575–580
   Google Scholar
• Jacob G. B., Hart K. K., Mullane J. F., Lutins S., Lee T. Y. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr: Ther: Res. 1983; 33: 703–71316. Jacob G. B., Hart K. K., Mullane J. F., Lutins S., Lee T. Y. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Curr: Ther: Res. 1983; 33: 703–713
   Web of Science ®Google Scholar
• Jacob G., Sanda M., Mullane J., Kennedy J., Baretti M., Suleski P. Long-term evaluation of the efficacy and safety of etodolac in the treatment of rheumatoid arthritis. Adv. Ther 1985; 2: 82–9517. Jacob G., Sanda M., Mullane J., Kennedy J., Baretti M., Suleski P. Long-term evaluation of the efficacy and safety of etodolac in the treatment of rheumatoid arthritis. Adv. Ther 1985; 2: 82–95
   Google Scholar
• Jallad N. S., Sanda M., Salom I. L., Perdomo C., Garg D. C., Mullane J. F., Weidler D. J. Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. Am. J. Med. Sci. 1986; 292: 272–29218. Jallad N. S., Sanda M., Salom I. L., Perdomo C., Garg D. C., Mullane J. F., Weidler D. J. Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. Am. J. Med. Sci. 1986; 292: 272–292
   PubMed Web of Science ®Google Scholar
• Joubert L., Mullane J. F., Merlo M., Martel R., Arnold J., Rolly G., Vetter G. Clinical pharmacological profile of Ultradol, a new nonsteroidal anti-inflammatory drug. Curr Ther: Res. 1982; 32: 744–8819. Joubert L., Mullane J. F., Merlo M., Martel R., Arnold J., Rolly G., Vetter G. Clinical pharmacological profile of Ultradol, a new nonsteroidal anti-inflammatory drug. Curr Ther: Res. 1982; 32: 744–88
   Google Scholar
• Koonce M. L., Levy M. E. Long-term study of etodolac in the treatment of patients with osteoarthritis. Todays Ther: Trends 1984; 2: 1–720. Koonce M. L., Levy M. E. Long-term study of etodolac in the treatment of patients with osteoarthritis. Todays Ther: Trends 1984; 2: 1–7
   Google Scholar
• Lanza F. L., Arnold J. D. Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies. Clin. Rheumatol. 1989; 8(Suppl. 1)5–1521. Lanza F. L., Arnold J. D. Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies. Clin. Rheumatol. 1989; 8(Suppl. 1)5–15
   PubMedGoogle Scholar
• Martel R. R., Klicius J. Anti-inflammatory and analgesic properties of etodolac in rats. Can. J. Phvsiol. Pharmacol. 1976; 54: 245–24822. Martel R. R., Klicius J. Anti-inflammatory and analgesic properties of etodolac in rats. Can. J. Phvsiol. Pharmacol. 1976; 54: 245–248
   PubMed Web of Science ®Google Scholar
• Ropes M. W., Bennet G., Caleb S., Jacox R., Jessar R. Revisions of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 1958; 9: 175–17623. Ropes M. W., Bennet G., Caleb S., Jacox R., Jessar R. Revisions of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 1958; 9: 175–176
   PubMedGoogle Scholar
• Salom I. L., Jacob G., Jallad N., Perdomo C. A., Mullane J. F., Weidler D. Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males. J Clin. Pharmacol. 1984; 24: 240–24624. Salom I. L., Jacob G., Jallad N., Perdomo C. A., Mullane J. F., Weidler D. Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males. J Clin. Pharmacol. 1984; 24: 240–246
   PubMed Web of Science ®Google Scholar
• Sanda M., Collins S. H., Mahady J., Huth J., Krantz K. Three-month multicenter study of etodolac (Ultradol) in patients with osteoarthritis of the hip. Curs Thes Rex. 1983; 33: 782–79225. Sanda M., Collins S. H., Mahady J., Huth J., Krantz K. Three-month multicenter study of etodolac (Ultradol) in patients with osteoarthritis of the hip. Curs Thes Rex. 1983; 33: 782–792
   Web of Science ®Google Scholar
• Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur: J. Rheumatol. Inflamm. 1990; 10: 56–6526. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur: J. Rheumatol. Inflamm. 1990; 10: 56–65
   PubMedGoogle Scholar
• Scott D., Scott D., Bacon P. Therapeutic progress – review VI. Treatment of rheumatoid arthritis. J. Clin. Hosp. Pharm. 1982; 7: 217–22927. Scott D., Scott D., Bacon P. Therapeutic progress – review VI. Treatment of rheumatoid arthritis. J. Clin. Hosp. Pharm. 1982; 7: 217–229
   PubMedGoogle Scholar
• Steinbrocker O., Traegar C. H., Batterman R. C. Therapeutic criteria in rheumatoid arthritis. J.A.M.A. 1949; 140: 659–66228. Steinbrocker O., Traegar C. H., Batterman R. C. Therapeutic criteria in rheumatoid arthritis. J.A.M.A. 1949; 140: 659–662
   PubMed Web of Science ®Google Scholar
• Taha A. S., McLaughlin S., Sturrock R. D., Russell R. I. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br. J. Rheumatol. 1989; 28: 329–33229. Taha A. S., McLaughlin S., Sturrock R. D., Russell R. I. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br. J. Rheumatol. 1989; 28: 329–332
   PubMedGoogle Scholar
• Versichelen L., Bilsback P., Rolly G., Merlo M., Joubert L. Etodolac in postsurgical pain: double-blind dose-ranging efficacy study with aspirin and placebo. Int. J. Clin Pharmacol. Ther: Toxicol. 1982; 20: 236–23930. Versichelen L., Bilsback P., Rolly G., Merlo M., Joubert L. Etodolac in postsurgical pain: double-blind dose-ranging efficacy study with aspirin and placebo. Int. J. Clin Pharmacol. Ther: Toxicol. 1982; 20: 236–239
   PubMedGoogle Scholar
• Waltham-Weeks C. D. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. Curr: Med. Res. Opin. 1987; 10: 540–54631. Waltham-Weeks C. D. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. Curr: Med. Res. Opin. 1987; 10: 540–546
   PubMed Web of Science ®Google Scholar